Actinium Pharmaceuticals, Inc.
ANTI-CD45-BASED CONDITIONING METHODS AND USES THEREOF IN CONJUNCTION WITH GENE-EDITED CELL-BASED THERAPIES

Abstract:

This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such as .sup.131I-BC8 or .sup.225Ac-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.